PROTACs
-
ReadFor protein degraders to tackle neurodegenerative diseases, these are the barriers they need to overcome
Neurodegenerative diseases (ND) and cancer are the two major targets in the pipelines of companies focused on targeted protein degradation as a therapeutic modality. Proteins involved in NDs —...
-
ReadWhy so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
-
ReadMST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
-
Characterizing interactions involving PROTACs or other TACs?
Find out how
NanoTemper tools can help -
ReadTargeted protein degradation promises to lead the way to effective drugs for challenging targets
-
35:47WatchImprove your protein degrader design with new ways to discover E3 ligase ligands
Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
-
Have a question?
Contact Specialist -
ReadDdi1 is a ubiquitin-dependent protease
-
ReadProtein degraders show promising results in drug development pipelines. See progress candidates have made.
There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...
-
Read
Are you building an effective protein degrader?
-
ReadAre you building an effective protein degrader? 4 questions to ask yourself to find out
Protein degraders are getting a lot of attention for being a new and promising modality to treat diseases such as cancer or Alzheimer’s disease. Rather than inhibiting the function of a protein,...
-
Read
Optimize the structure of your next round of PROTAC compounds by analyzing ternary binding affinities using Monolith
-
Read6 protein degradation conferences in 2021 you can’t afford to miss
Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation (TPD). Many transcription factors, scaffold proteins,...
-
59:35WatchUnderstanding the nuances of targeted protein degradation
Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte
-
17:10WatchTackle the high-hanging fruits in challenging drug discovery pipelines
There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t
-
Read
Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus
-
ReadSweet and blind spots in E3 ligase ligand space revealed by a thermophoresis-based assay
-
ReadWhat are PROTACs: the game-changing modality that promises to tackle undruggable proteins
Almost all pharmaceutical drugs today act by binding to disease-causing proteins and inhibiting their activity. Unfortunately, there are still many target proteins — as much as 85% of the human...
-
ReadTargeting the SARS-CoV‑2 RNA genome with small molecule binders and ribonuclease targeting chimera (RIBOTAC) degraders
-
ReadTargeted degradation of a hypoxia-associated non-coding RNA enhances the selectivity of a small molecule interacting with RNA
-
ReadThe peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
-
ReadA cell-permeable peptide-based PROTAC against the oncoprotein CREPT proficiently inhibits pancreatic cancer
-
Loading more...
